Publication Ethics and Malpractice Statement
 

International Journal of Pharma Insight Studies

The International Journal of Pharma Insight Studies is committed to maintaining the highest standards of ethical scholarly publishing. The journal promotes integrity, transparency, and accountability across all stages of the editorial and publication process and follows internationally recognized principles of publication ethics.

This statement defines the ethical responsibilities of authors, reviewers, editors, and the publisher.

The journal ensures complete editorial independence in decision-making. Manuscripts are evaluated exclusively on academic merit and ethical compliance.

Editors are responsible for:

1. Making unbiased publication decisions based on scientific quality and relevance
2. Ensuring confidentiality of manuscripts and communications
3. Preventing conflicts of interest in the editorial process
4. Safeguarding the integrity of the scholarly record

Editors must withdraw from handling submissions where a conflict of interest exists.

Peer review is a cornerstone of the journal’s quality control mechanism and is conducted in a fair, confidential, and objective manner.

Reviewers are expected to:

1. Provide objective, constructive, and timely evaluations
2. Treat all manuscripts as confidential documents
3. Avoid using unpublished information for personal benefit
4. Declare conflicts of interest and decline review when necessary

The journal does not tolerate biased, defamatory, or unprofessional reviewer conduct.

Authors are accountable for the integrity and accuracy of their submitted work.

Authors must ensure that:

1. The manuscript is original and not under review elsewhere
2. All sources and references are properly cited
3. Data presented is accurate, complete, and verifiable
4. Funding sources and conflicts of interest are fully disclosed

Authorship Principles

Authorship is limited to individuals who have made substantial intellectual contributions to the research.
Practices such as guest, gift, or ghost authorship are strictly prohibited.

All authors must approve the final manuscript prior to submission.

For studies involving humans or animals, authors must adhere to recognized ethical standards.

This includes:

1. Obtaining necessary ethical approvals
2. Ensuring informed consent where applicable
3. Clearly stating ethical compliance within the manuscript

Failure to meet ethical research standards may result in rejection or retraction.

The journal applies standard plagiarism detection and editorial screening procedures.

Unacceptable practices include:

1. Plagiarism or self-plagiarism
2. Duplicate or redundant publication
3. Data fabrication or falsification
4. Citation manipulation
5. Authorship disputes or misrepresentation

Allegations of misconduct are investigated thoroughly, and appropriate corrective actions are taken.

The journal is committed to preserving the accuracy of the academic record.

Where necessary, the journal may publish:

1. Corrections for honest errors
2. Expressions of concern for unresolved issues
3. Retractions for serious ethical violations

All notices remain permanently linked to the original article.

The publisher supports ethical publishing practices and ensures that:

1. Editorial independence is fully respected
2. Commercial interests do not influence editorial decisions
3. Ethical standards are upheld throughout the publication lifecycle

This Ethics Policy is reviewed periodically to ensure alignment with evolving international best practices in scholarly publishing.

Submission of a manuscript to the International Journal of Pharma Insight Studies implies full acceptance of this Publication Ethics and Malpractice Statement.